1uyc: Difference between revisions
No edit summary |
No edit summary |
||
| Line 39: | Line 39: | ||
[[Category: pu7]] | [[Category: pu7]] | ||
''Page seeded by [http://ispc.weizmann.ac.il/oca OCA ] on Tue Oct 30 | ''Page seeded by [http://ispc.weizmann.ac.il/oca OCA ] on Tue Oct 30 16:15:15 2007'' | ||
Revision as of 17:10, 30 October 2007
|
HUMAN HSP90-ALPHA WITH 9-BUTYL-8-(2,5-DIMETHOXY-BENZYL)-9H-PURIN-6-YLAMINE
OverviewOverview
Inhibition of the ATPase activity of the chaperone protein HSP90 is a, potential strategy for treatment of cancers. We have determined structures, of the HSP90alpha N-terminal domain complexed with the purine-based, inhibitor, PU3, and analogs with enhanced potency both in enzyme and, cell-based assays. The compounds induce upregulation of HSP70 and, downregulation of the known HSP90 client proteins Raf-1, CDK4, and ErbB2, confirming that the molecules inhibit cell growth by a mechanism dependent, on HSP90 inhibition. We have also determined the first structure of the, N-terminal domain of HSP90beta, complexed with PU3. The structures allow a, detailed rationale to be developed for the observed affinity of the PU3, class of compounds for HSP90 and also provide a structural framework for, ... [(full description)]
About this StructureAbout this Structure
1UYC is a [Single protein] structure of sequence from [Homo sapiens] with PU7 as [ligand]. Structure known Active Site: AC1. Full crystallographic information is available from [OCA].
ReferenceReference
Structure-activity relationships in purine-based inhibitor binding to HSP90 isoforms., Wright L, Barril X, Dymock B, Sheridan L, Surgenor A, Beswick M, Drysdale M, Collier A, Massey A, Davies N, Fink A, Fromont C, Aherne W, Boxall K, Sharp S, Workman P, Hubbard RE, Chem Biol. 2004 Jun;11(6):775-85. PMID:15217611
Page seeded by OCA on Tue Oct 30 16:15:15 2007